Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 315,522 shares of Roivant Sciences stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $11.06, for a total value of $3,489,673.32. Following the sale, the chief operating officer now owns 959,457 shares of the company's stock, valued at approximately $10,611,594.42. This trade represents a 24.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Eric Venker also recently made the following trade(s):
- On Monday, March 24th, Eric Venker sold 434,478 shares of Roivant Sciences stock. The stock was sold at an average price of $10.82, for a total transaction of $4,701,051.96.
- On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00.
- On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The stock was sold at an average price of $10.42, for a total transaction of $2,271,987.22.
- On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.28, for a total value of $1,128,000.00.
- On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The stock was sold at an average price of $11.54, for a total value of $2,050,704.16.
- On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The shares were sold at an average price of $11.82, for a total value of $2,090,958.00.
Roivant Sciences Price Performance
Shares of ROIV stock traded down $0.14 during mid-day trading on Friday, hitting $10.35. 871,987 shares of the stock traded hands, compared to its average volume of 5,534,777. Roivant Sciences Ltd. has a 52-week low of $9.96 and a 52-week high of $13.06. The stock has a market cap of $7.38 billion, a P/E ratio of -68.96 and a beta of 1.26. The stock's fifty day moving average is $10.76 and its two-hundred day moving average is $11.43.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, equities analysts forecast that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.
Analyst Ratings Changes
Several brokerages have recently commented on ROIV. HC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $17.10.
Read Our Latest Stock Analysis on ROIV
Institutional Investors Weigh In On Roivant Sciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. increased its holdings in shares of Roivant Sciences by 478.6% during the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after acquiring an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Roivant Sciences during the 4th quarter worth approximately $39,000. GAMMA Investing LLC increased its position in shares of Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock valued at $42,000 after acquiring an additional 1,288 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Roivant Sciences by 27.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after acquiring an additional 1,507 shares during the period. Finally, Quarry LP increased its holdings in shares of Roivant Sciences by 50.0% in the third quarter. Quarry LP now owns 7,500 shares of the company's stock valued at $87,000 after purchasing an additional 2,500 shares during the period. 64.76% of the stock is currently owned by hedge funds and other institutional investors.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
